With theprecision and intelligent diagnosis as the core business, DIAN Diagnostics promotes the implementation of innovation-driven technology leading strategy.In view of the requirements of clinical customers for more precise, morecomprehensive and more personalized tests in the times of precision medicaltreatment, we continuously upgrade the technical platform and expand the testitems detect the expansion of the project around the biochemistry, humanimmunological analysis, microbial pathogen analysis, hematological analysis,metabolomics analysis, gene sequencing and molecular biological detection,pathologic diagnosis and other diagnosis platforms. In particular, with the NGSsequencing platform and mass-spectrometric technique gradually moving towards theclinical, the remote pathology and MDT diagnosis and treatment model graduallygaining popularity, the advantages of independent laboratory are highlighted.
Create acomprehensive genetic sequencing platform and clinical promotion model with thegenetics and tumor genomics as the core.
Based on the approved national genetic testing technologyclinical application demonstration center and licensed pilot qualification, wehave passed the external quality assessment of the sequencing of fetalchromosomal aneuploid gene in peripheral blood, tumor diagnosis and highthroughput gene sequencing test project for targeted therapy for twoconsecutive years, and our laboratory testing service abilities have gainedhigh recognition by the customers.
DIAN Diagnostics iscommitted to building an effective promotion model for the clinicalapplication. On the one hand, we cooperate with the National Health and FamilyPlanning Commission, and joint hand with Zhejiang-California InternationalNanosystems Institute to undertake the genetic counseling training program inZhejiang Province, to develop more qualified genetic counselors for Zhejiangand even the whole country, thus promoting the development of precisionmedicine in China. On the other hand, the company selects Top threebenchmarking hospital-- Sir Run Run Shaw Hospital affiliated with ZhejiangUniversity School of Medicine to co-establish the "Precision Medicine Centerin Zhejiang Province".
Leverage the mass spectrometry technology to developprecision medical treatment with the metabolomics as the core business.
Mass-spectrometric technique, the testingtechnology that has been lingering in the research institutes for a long term,has gradually attracted the attention of the laboratory medicine due to itshuge potential clinical application prospects. At present, domestic applicationof mass spectrometry in clinical medicine is still in its infancy, with greatpotential. The company has introduced a number of senior expert teams with richexperience in mass spectrometry and many years of practice in the clinicaldiagnosis and pharmaceutical industry in North America to set up the holdingsubsidiary - Kailaipu Precision Medical Treatment, committed to building afirst-class mass spectrometry application platform in China, includingmetabolomics, Pharma CRO and forensic toxicological detection, etc.Comprehensive testing items such as vitamin family, amino acid family,steroids, organic acids, fatty acids, nutrients and toxic elements, plasmaconcentration and others have been carried out on the existing mass spectrometryplatform of the company. Technical research and development in the field ofmetabolomics will be further expanded subsequently, with the promotion in theclinical validation and product registration, to make active use the channelresources of the company to increase the scope of clinical applications.
We have reached the cooperation intention withthe international leading metabolomics service provider METABOLON, and willestablish an exclusive authorized laboratory in Hangzhou, to introduce andgraft the international advanced technologies in metabolomics to the Chinesemedical market, serving for the clinical diagnosis, life science drug research,personal health examination and others in the early intervention in the tumorand diagnosis, prevention and control of diabetes, functional medicine andother aspects. We will also provide strong metabolomics support for thescientific studies of large cohort, to facilitate the domestic application ofhigh-end mass spectrometry diagnostic technology.